Trial4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Trial details
- Registry ID
- NCT06864988
- Phase
- Phase 3
Drug research
EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT06864988 | 4D Molecular Therapeutics | Phase 3 | Active not recruiting | 2027-06Estimated |
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT07064759 | 4D Molecular Therapeutics | Phase 3 | Recruiting | 2028-11Estimated |
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Trial details
- Registry ID
- NCT07064759
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |